Analysed CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) News Sources
Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More
07-08-2026
yahoo.com
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
02-04-2026
yahoo.com
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results
06-05-2026
yahoo.com
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
18-05-2026
yahoo.com
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
15-06-2026
yahoo.com
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
15-06-2026
yahoo.com
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10-07-2026
yahoo.com
What is the current price of CONTEXT THERAPEUTICS INC (CNTX:NASDAQ)?
The current price of CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) is $0.3504.
CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) since the previous trading day is $-0.016.
CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) since the previous trading day is -4.3668%.
What is the most recent average sentiment score for CONTEXT THERAPEUTICS INC (CNTX:NASDAQ)?
The most recent average sentiment score for CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for CONTEXT THERAPEUTICS INC (CNTX:NASDAQ)?
The most recent sentiment for CONTEXT THERAPEUTICS INC (CNTX:NASDAQ) is .
SEC-8K** Filing Available For CONTEXT THERAPEUTICS INC (CNTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.